Evolving Treatment Strategies in the Management of Hyperkalemia: Managed Care Considerations for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca

Description:
Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Normal potassium levels are between 3.5 and 5.0 mmol/L with levels above 5.5 mmol/L defined as hyperkalemia. Typically, this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD), hypertension, and heart failure. Chronic hyperkalemia is a challenging clinical problem associated with increased mortality in patients with CKD and HF. The risk of hyperkalemia is also a limiting factor in using renin-angiotensin aldosterone system (RAAS) inhibitors for the treatment of hypertension, chronic kidney disease, heart failure, and diabetes. Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety in lowering potassium levels and improving patient outcomes. Additionally, some of these options have shown the ability in recent clinical trials to reduce arrhythmia-related cardiovascular outcomes in patients’ hyperkalemia.


 Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of hyperkalemia and the impact of suboptimal management on outcomes

  • Explain the importance of a healthy diet in a patient with hyperkalemia and the quality-of-life impact of potassium-restricted diet

  • Compare and contrast the safety, efficacy, labeling, dosing and role of potassium binders in the management of hyperkalemia in a variety of settings and populations

  • Analyze the emerging role of potassium binders to reduce arrhythmia-related cardiovascular outcomes in patients with hyperkalemia

  • Identify patients with hyperkalemia with end stage renal disease who would potentially benefit from a novel potassium binder therapy

  • Integrate the latest clinical and pharmacoeconomic data on potassium binders into evidence-based formulary decisions and benefits design

     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

 (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Owens has no relevant financial relationship with an ineligible company to disclose.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue